Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Find the Historical backdrop of Common liberties: Advancing Equity and Equity Around the world - 2Protest inspired by 'Gen Z' movement draws few young people in Mexico and many government critics
- 3Dental, Vision, and Hearing Inclusion in Senior Protection.
- 4Eli Lilly to build $6 billion Alabama plant as part of US manufacturing push
- 5Blood pressure drug recalled for possible cross-contamination
- This Asian country is the next hot travel destination, and this is one of its best hotels
- Rio Tinto resumes operations at three Pilbara port terminals after cyclone Narelle
- Explosions heard across Tehran after IDF announces wave of strikes on regime terror targets
- Building a Flourishing Business: Illustrations from Business people
- Like 'accelerating from stationary to supersonic flight': Europe's Hera probe boosts speed, stays on course for November asteroid rendezvous
- Illustrations Gained from a Crosscountry Excursion
- Instructions to Expand Your Advantages from an Open Record Reward
- The Best Music Collections of the 10 years
- Miley Cyrus flashes a diamond ring on the red carpet, sparking engagement rumors with Maxx Morando: A timeline of their four-year relationship
